



Treatment Options for Plaque Psoriasis: Effectiveness, Value, & Value-Based Price Benchmarks

Friday, November 18, 2016; 10:00 AM – 4:30 PM

Joseph B. Martin Conference Center | Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

Time	Activity
9:30 am – 10:00 am	Registration
10:00 am – 10:15 am	Meeting Convened and Opening Remarks: <ul style="list-style-type: none"> Steven Pearson, MD, MSc, President, ICER
10:15 am – 11:30 am	Presentation of the Evidence: <ul style="list-style-type: none"> Jeffrey Linder, MD, MPH, Harvard Medical School David Veenstra, PharmD, PhD, University of Washington Rick Chapman, PhD, MS, ICER
11:30 am – 11:45am	Public Comments and Discussion <i>Members of the public pre-registered to deliver oral remarks</i>
11:45am – 12:15 pm	Manufacturer Comments and Discussion
12:15pm – 1:00 pm	Break for Lunch
1:00 pm – 2:00 pm	New England CEPAC Q&A with Clinical and Patient Experts New England CEPAC Deliberation and Votes: <i>ICER staff and clinical experts will be available for questions from the Council during deliberation</i>
2:00 pm – 3:15 pm	Policy Roundtable
3:15 pm – 3:45 pm	New England CEPAC Reflections
4:00 pm	Meeting Adjourned

Institute for Clinical and Economic Review (ICER) Staff and Consultants

Rick Chapman, PhD, MS, Director of Health Economics
Nathaniel Hendrix, PharmD, University of Washington
Sarah Emond, MPP, Chief Operating Officer
Varun Kumar, MBBS, MPH, MSc, Health Economist
Jeffrey Linder, MD, MPH, Brigham & Women’s Hospital
Shanshan Liu, MS, MPH, Research Associate
Anne Loos, MA, Senior Research Associate

Dan Ollendorf, PhD, Chief Scientific Officer
Steve Pearson, MD, MSc, President
David Rind, MD, MSc, Chief Medical Officer
Mitchell Stein, MBA, Policy and Communications Director
Celia Segel, MPP, Program Manager
Dave Veenstra, PhD, PharmD, University of Washington
Maggie Webb, BA, Program and Event Coordinator

Participating Members of New England CEPAC

<p>Robert H. Aseltine, Jr., PhD Professor in the Division of Behavioral Sciences and Community Health, Deputy Director of the Center for Public Health and Health Policy, and Director of the Institute for Public Health Research University of Connecticut</p>	<p>Stephanie Nichols, PharmD, BCPS, BCPP Associate Professor of Pharmacy Practice, Husson University Psychiatric Pharmacist, Maine Medical Center</p>
<p>Gregory Curfman, MD Editor in Chief, Harvard Health Publications Harvard Medical School</p>	<p>Julia Prentice, PhD Director, Health Care Financing and Economics VA Boston Healthcare System</p>
<p>Teresa Fama, MD, MS (Chair) Physician, Central Vermont Rheumatology</p>	<p>Roger Snow, MD, MPH Former Deputy Medical Director, Medical Policy Commonwealth of Massachusetts, Office of Medicaid</p>
<p>Austin Frakt, PhD Health Economist, VA Boston Healthcare System Associate Professor, Boston Univ. School of Public Health Associate Professor, Boston Univ. School of Medicine</p>	<p>Keith A. Stahl, MD Executive Medical Director, Primary Care and Population Health, Catholic Medical Center</p>
<p>Claudio Gualtieri, JD Associate State Director of Advocacy, Connecticut AARP</p>	<p>Jason Wasfy, MD, MPhil Assistant Medical Director, Massachusetts General Physicians Organization Director of Quality and Analytics, Massachusetts General Hospital Heart Center</p>
<p>Christopher Jones, PhD Asst. Professor of Surgery Asst. Professor of Economics University of Vermont College of Medicine</p>	<p>Edward Westrick, MD, PhD <i>Primary Care Physician, Assistant Medical Director</i> Comprehensive Community Action Program</p>
<p>Stephen Kogut, PhD, MBA, RPh <i>Professor of Pharmacy Practice</i> University of Rhode Island College of Pharmacy</p>	<p>Rev. Albert Whitaker, MA Director of Community Partnerships, New England American Diabetes Association</p>
<p>Kimberly Lenz, PharmD (ex-officio) Clinical Pharmacy Manager MassHealth</p>	

**All members of the New England CEPAC meet specified COI standards. COI is defined as: A specific financial association in excess of \$25,000 during the previous year from any one health care manufacturer or insurer; or financial association, such as individual health care stock ownership in excess of \$50,000 in aggregate during the previous year from health care manufacturers or insurers.*

Policy Roundtable

<p>Joseph F. Merola, MD, MMSC Department of Dermatology Harvard Medical School Director of the Clinical Unit for Research Innovation & Trials; Director of the Center for Skin & Related Musculoskeletal Diseases Brigham and Women's Hospital</p>	<p>Paul Jeffrey, PharmD Director of Pharmacy; Office of Clinical Affairs University of Massachusetts Medical School; MassHealth (Massachusetts Medicaid)</p>
<p>Leah McCormick Howard, JD Vice President of Government Relations and Advocacy National Psoriasis Foundation</p>	<p>Chris Pettit Patient Advocate Portland, Oregon</p>
<p>Abby S. Van Voorhees, MD Chair, Department of Dermatology Eastern Virginia Medical School Chair, National Psoriasis Foundation</p>	<p>Thomas Kowalksi, RPh Clinical Pharmacy Director, Health and Medical Management Blue Cross Blue Shield of Massachusetts</p>